In February 2026, The Wall Street Transcript published an exclusive interview with CytoMed Therapeutics Ltd (NASDAQ: GDTC) Chairman Choo Chee Kong. The interview covered the company’s... Read More
CytoMed
In February 2026, The Wall Street Transcript published an exclusive interview with CytoMed Therapeutics Ltd (NASDAQ: GDTC) Chairman Choo Chee Kong. The interview covered the company’s... Read More
In Singapore, one biotech company is changing how we approach cancer treatment. CytoMed Therapeutics (NASDAQ: GDTC), just launched its ANGELICA clinical trial, to fundamentally change how we make... Read More
In February 2026, The Wall Street Transcript published an exclusive interview with CytoMed Therapeutics Ltd (NASDAQ: GDTC) Chairman Choo Chee Kong. The interview covered the company’s... Read More
CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable... Read More

CytoMed Therapeutics Ltd — An Emerging Star in Singapore’s Cancer Biotechnology Sector
CytoMed Therapeutics Ltd (NASDAQ: GDTC) – A Rising Star in Singapore’s Cancer Biotechnology Sector
CytoMed, a Singapore Biotech, Revolutionizes Cancer Treatment Using Donor Immune Cells
CytoMed Therapeutics Ltd — A Rising Star in Singapore’s Cancer Biotechnology Sector
CytoMed Therapeutics Limited is accelerating its international expansion